Abstract
Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.
Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials
Reviews on Recent Clinical Trials
Title: Dendritic Cell Immunotherapy for Melanoma
Volume: 1 Issue: 2
Author(s): Judy C. Peng, Ranjeny Thomas and Keith Dredge
Affiliation:
Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials
Abstract: Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.
Export Options
About this article
Cite this article as:
Peng C. Judy, Thomas Ranjeny and Dredge Keith, Dendritic Cell Immunotherapy for Melanoma, Reviews on Recent Clinical Trials 2006; 1 (2) . https://dx.doi.org/10.2174/157488706776876517
DOI https://dx.doi.org/10.2174/157488706776876517 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design Photoperiod and Testosterone Modulate Growth and Melanogenesis of S91 Murine Melanoma
Medicinal Chemistry Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Biotransformation of Bioactive Natural Products for Pharmaceutical Lead Compounds
Current Organic Chemistry Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Long Noncoding RNA C21orF96 Promotes the Migration, Invasion and Lymph Node Metastasis in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Current Gene Therapy s-Proline Covalented Silicapropyl Modified Magnetic Nanoparticles: Synthesis, Characterization, Biological and Catalytic Activity for the Synthesis of thiazolidin-4- ones
Current Organic Synthesis